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Introduction
The HIV/AIDS epidemic remains a global health challenge of unprecedented dimensions and a
monumental threat to development progress.1 To date, more than 25 million people worldwide have
died from HIV-related complications. The number of people living with HIV worldwide continues to
grow and reached an estimated 33.4 million in 2008.2
The spread of the epidemic continues to outpace the

HIV/AIDS has also become one of the greatest threats to

world’s response to it, even with a 10-fold increase in

women’s health. HIV/AIDS is the leading cause of death

antiretroviral (ARV) treatment made available in low- and

globally in women ages 15–44, and exacts a particularly

middle-income countries from 2003–2008. For every

high toll in sub-Saharan Africa where the epidemic

two people placed on ARV therapy, five more individuals

has hit hardest, according to the latest comprehensive

become infected with the virus.     

data from the World Health Organization. Women account

Sub-Saharan Africa continues to disproportionately bear

for 60 percent of those living with the disease in

3
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the global HIV/AIDS burden. Two-thirds of all people

sub-Saharan Africa.6

newly infected with HIV live in that region, and 72 percent

These harsh realities threaten progress toward the

of all AIDS deaths in 2008 occurred there.

UN Millennium Development Goals (MDGs), which 189

5

United Nations member states adopted in 2000 with the
objective of meeting them by 2015. The eight goals create
a universal framework for development that envisions a
better future for all people.

MDGs: Progress, Challenge
and the Hope of Microbicides
Despite the challenges, the world is committed to fulfilling
the MDG promises. The MDGs represent commitments
from both developed and developing countries, and
define progress through quantifiable development
targets. Nations acknowledge the overriding importance
of strengthening the response to HIV/AIDS in Goal 6,
which aims to halt and begin to reverse the HIV pandemic
by 2015. This was reinforced during the first Special
Session on HIV/AIDS of the United Nations General
Assembly (UNGASS) in 2001, where member nations
endorsed the Declaration of Commitment on HIV/AIDS.
The Declaration acknowledged that gender equality and
women’s empowerment could reduce women’s and girls’
vulnerability to HIV.
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In 2008, UNAIDS noted that although some countries are
on course to meet the targets outlined in the Declaration

Millennium Development Goals

of Commitment, others are not. The reasons for slow

Goal 1: Eradicate extreme poverty and hunger

progress are complex and often linked, though HIV/AIDS is

Goal 2: Achieve universal primary education

a significant factor.8 These or similar targets will continue

Goal 3: Promote gender equality and empower women

7

to guide development efforts well beyond 2015.
Achieving the MDG goals will require that key
stakeholders:

Goal 4: Reduce child mortality
Goal 5: Improve maternal health
Goal 6: Combat HIV/AIDS, malaria and other diseases

ffbuild political will and leadership

Goal 7: Ensure environmental sustainability

ffimprove public policies

Goal 8: Develop a global partnership for development

ffintensify and scale up programs that work
ffinvest in the development of new global public health

At the review Summit, IPM pledged to support the Global

strategies such as effective prevention technologies

Strategy on Women’s and Children’s Health by continuing

One such promising prevention technology is ARV-based
microbicides — medical products being developed to
prevent HIV transmission to women during sex with an
infected male partner. These HIV prevention products
contain the same types of ARV drugs currently being used
to successfully treat HIV/AIDS.
Clinical trial results announced in July 2010 offer great
reason for optimism. The trial, called CAPRISA 004, showed
“proof-of-concept” that an ARV-based microbicide vaginal
gel can prevent HIV infection in women. Such ARV-based
microbicides are currently in clinical development by the
International Partnership for Microbicides (IPM) and other
nonprofit organizations. Because they are user-initiated,
microbicides could put the power of prevention into
women’s hands.  
During the 2010 UN review of the MDGs, member states
revived efforts to achieve the goals within the next
five years and announced major new commitments
for women’s and children’s health. Their global action
plan promised to accelerate progress to achieve MDG 6
(combating HIV/AIDS, malaria and other diseases) through
significantly intensifying HIV prevention efforts, and
advance research and development into new prevention
tools, including microbicides.9

to progress microbicide research and product delivery, and
to provide women worldwide with new tools to safeguard
their health — and their families’. Inspired by women’s
urgent need for new prevention tools and supported by
landmark data from the CAPRISA trial showing proof-ofconcept for ARV-based microbicides, IPM is committed to
turning this hope into a scientific reality.
Ensuring that new HIV prevention technologies such as
microbicides are accessible to those who need them most
requires coordination from all levels of the international
community. To help guarantee success, Goal 8 calls for
creating a global partnership for development. This goal is
particularly relevant for making certain that, once available,
female-initiated microbicides could quickly be approved for
use and distributed to those women most in need.  

Feminization of HIV
Although the epidemic varies from country to country in
sub-Saharan Africa, women are disproportionately affected
compared with men — a disparity far greater among young
women and men. In some countries, HIV prevalence is
three times higher among women ages 15 to 24 than it is
among men of the same age.10 As noted in the Report of
the Secretary-General on the Declaration of Commitment
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on HIV/AIDS and Political Declaration on HIV/AIDS in
2008: Gender inequities fuel the continued spread of

“Successful prevention means continuing to invest in

HIV, reducing women’s ability to protect themselves

prevention research and development — particularly

from sexual transmission, increasing their vulnerability to

for microbicides, vaccines and pre-exposure

sexual violence and placing them in circumstances where

prophylaxis — as we continue to work towards a cure.

their risk of acquiring HIV is greater.

It means forging a prevention movement.”

11

Heterosexual intercourse remains the primary method
of HIV transmission in sub-Saharan Africa.12 Power
imbalances between men and women as well as

Michel Sidibé, UNAIDS Director
2009 UNAIDS Programme Coordinating Board Meeting
Geneva

gender stereotypes contribute to the “feminization” of
the HIV epidemic.13 If women want to use condoms or
abstain from sex, they often lack the ability to do so.14
These complex social issues are further complicated by
women’s greater biological vulnerability to the virus.
For these reasons, HIV prevention strategies must be
targeted to women. Combination prevention approaches
based on sound evidence that include system changes,
behavioral approaches and medical strategies — such as
microbicides — are necessary to end the feminization of
the disease.

HIV Prevention for Women:
Impact on the MDGs
Reducing HIV infection in women and girls is critical to
Goal 1, breaking the cycle of poverty and hunger. Rural
women in particular are responsible for producing half of
the world’s food — in most developing countries, women

produce between 60 percent and 80 percent of food.15  
Production suffers when women fall ill from HIV-related
complications or must look after sick family members.
In the hardest hit countries, women and girls continue
to bear the burden of caring for people living with HIV.16
These female caregivers have little time to earn income,
produce food, go to school or support their families.
Along with their families, these caregivers are more likely
to be malnourished, in poor health or economically
destitute — all factors that further increase their risk for
HIV infection.

Keeping girls in school
Reducing the spread of HIV is therefore critical to keeping
girls in school and achieving Goal 2, establishing universal
primary education. HIV-related death and illness cause
shortages in teaching staff. The illness of a parent or
family member often means that girls are withdrawn from
school to care for that parent and younger siblings. When
a parent dies, girls are also more likely than boys to leave
school to take over agricultural and income support roles
that will sustain their families.17

Enhancing gender equality
Goals 3 and 5 both seek to enhance gender equality
and women’s health. HIV rates among women have
been linked to women’s political, social and economic
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disempowerment, and evidence shows that sexual and
reproductive health and rights are central to a woman’s
ability to build on her capabilities and control her future.

18

Women’s vulnerability to HIV directly affects
progress towards Goals 1, 2 and 4:
Goal 1: Eradicate extreme poverty and hunger

Improving maternal health

Goal 2: Achieve universal primary education

Maternal health and the HIV/AIDS epidemic intersect all

Goal 4: Reduce child mortality

too often, especially in high-burden countries such as
South Africa and Zimbabwe, where HIV is the leading

Three of the eight MDGs are directly related to
the health and rights of women:

cause of maternal mortality.19

Goal 3: Promote gender equality and empower women

Efforts to improve maternal health and meet Goal 5

Goal 5: Improve maternal health

are moving ahead, but the HIV epidemic has had an

Goal 6: Combat HIV/AIDS, malaria and other diseases

adverse effect on efforts to reduce maternal mortality
rates. Pregnant, HIV-positive women may actually see
the progression of the disease worsen during their

When women and girls have little control over the

pregnancies.20 HIV is a leading indirect cause of maternal

conditions under which sexual intercourse takes place,

mortality in regions with high incidence of HIV/AIDS.21

prevention approaches such as using condoms, behavior

In fact, without HIV there would have been 60,000 fewer

change and mutual monogamy are unrealistic. The

maternal deaths in 2008.22

efficacy of male circumcision in reducing female-tomale HIV transmission has been proven, but it does not

Reducing childhood mortality
Reducing HIV infection rates in women will reduce the
number of children born with HIV and help achieve
Goal 4 by reducing child mortality. Globally, AIDS
is responsible for about 3 percent of child deaths.23
Although new infections in children are declining, an

provide complete protection.25  Nor is it known whether
male circumcision reduces HIV transmission from men
to women. An HIV/AIDS vaccine, and oral prevention
pills or injections (also known as “PrEP” or pre-exposure
prophylaxis) have the potential to provide additional
prevention options in the future, and are in development.

estimated 90 percent of children living with HIV acquired

There is an urgent need for female-initiated HIV

the virus during birth or breastfeeding, or when their

prevention strategies, such as microbicides, that do

mothers were pregnant. Women who can protect

not interfere with intimate relations and are not

themselves against HIV infection can preserve their

necessarily contraceptive.

24

families, which will reduce the number of orphaned

The Potential of Safe and
Effective Microbicides

children.

Current Methods Fail to Meet
Women’s Needs

Vaginal microbicides would complement existing

Although a range of prevention strategies exists, current

would serve as a prevention tool for women who are

methods have not significantly lowered the rate of new

unable to access or use other methods. Most important,

infections — particularly among women.  

these products would address one of the central gaps

prevention methods and others being developed, and
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in the existing continuum of HIV prevention options by
offering a discreet method that women could use to

“Women in their productive years bear the brunt of

protect themselves.

HIV more than any other group in the population

The first microbicides to be studied were compounds that
did not specifically target HIV. Several of these earlygeneration products were tested in large-scale efficacy
trials, typically in the form of vaginal gels, but none were
shown to be effective tools for HIV prevention.

but the methods we have so far – condoms, male
circumcision – only work if the man is prepared to
accept them. Young women with [microbicides] will
be able to take their health into their own hands.”
Aaron Motsoaledi, SA Minister of Health
AIDS Map, July 20, 2010

In the last few years, researchers have made progress in
developing  a new class of microbicides based on the
same types of antiretroviral compounds being used
successfully to treat millions of people who are already
infected with the virus and to prevent mother-to-child
transmission of HIV. As noted earlier, the recent findings
from CAPRISA study, the first clinical trial of an ARV-based

The global HIV epidemic cannot be

of the time of sexual activity, such as once-daily vaginal
gels, films, tablets and vaginal rings that would provide a
month’s protection from HIV.
Researchers are testing single and combination products,
and conducting acceptability studies in several countries
to help determine the types of products women and
their partners would really want and use. Developing

reversed without effective and tailored

microbicides in a variety of forms would help ensure their

HIV prevention strategies.

wide acceptability and use.

microbicide, demonstrated proof-of-concept that an ARV-

Investment in Microbicides and
Women Who Need Them

based vaginal gel can offer women protection

If a second, multi-center clinical trial confirms the CAPRISA

against HIV.

trial’s findings for tenofovir and the global community

These highly potent next-generation products specifically

adequately funds microbicide research, the first

target HIV from the moment the virus enters the

microbicide product might be registered as early as 2013.  

vagina during intercourse. ARV-based microbicides are

In 2009, total global investment in microbicide research

being developed to work in a variety of ways by either

was US $236 million, which is a 3 percent decrease since

preventing the HIV virus from attaching to or entering

2008 and the first year-to-year decline since 2000.26

a healthy human cell, or by preventing the virus from

A number of pharmaceutical companies have contributed

making copies of itself once it is inside a cell. Tenofovir
gel, the ARV-based microbicide tested in the CAPRISA  
trial,  prevents HIV from copying its genetic material
inside healthy cells.   

to microbicide development by granting royalty-free
licenses to use their ARV compounds for research. Since
its inception in 2002, IPM has obtained non-exclusive,
royalty-free licenses from five pharmaceutical companies

ARV-based microbicides would come in a variety of

to develop a number of ARV-based compounds as

formulations that could be used around the time of sex or

microbicides: Bristol-Myers Squibb, Gilead Sciences,

longer-acting products that would be used independent

Merck, Pfizer and Tibotec Pharmaceuticals.
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These partnerships and licensing agreements ensure
that when IPM develops an effective microbicide, it will
be accessible to women in developing countries at low
or no cost. IPM’s other partners include host country
governments, universities, scientific communities that
assist in research, global health leaders whose support
furthers research and donors who continue to support
microbicide research and development. IPM also partners
with a variety of nongovernmental organizations in Africa
and elsewhere, working together on a variety of issues
related to women’s health and rights, and HIV prevention.

Long-term Prevention: A Call to Action
The response to HIV has focused on addressing
its devastating impact on people. Indeed, HIV is a
humanitarian issue.
The epidemic also has fundamentally affected many
countries’ development performance, which makes it
difficult for many resource-poor countries to reach MDG
targets before 2015 or even in the more distant future.
The global HIV epidemic cannot be reversed without
effective and tailored HIV prevention strategies. It is
reassuring that global leaders recognize the need to
support comprehensive prevention strategies that can
protect a wide range of populations from HIV infection
and the urgent need for a HIV prevention tool that women
can use to protect their own health, especially given
women’s greater vulnerability to HIV infection.
The results of the CAPRISA 004 clinical trial are very
encouraging and also indicate the potential and the
need for products with even higher efficacy. Increased
investment in a wide range of new prevention
technologies, including ARV-based microbicide products,
is needed to stem the spread of the HIV/AIDS epidemic.

IPM is a nonprofit product development
partnership (PDP) that brings together private
sector technologies and public sector resources
to fulfill its mission to develop microbicides for
women in urgent need of HIV prevention options.
PDPs work closely with researchers in developing
countries to create affordable medical products
for use there, and help to build these countries’
capacities and infrastructure. PDPs received high
marks for their impact on improving public health
in developing countries, as noted in the World
Health Organization 2010 Expert Working Group
Report on Research and Development Financing
and Coordination.27
The PDP model is built on successful partnerships
with a variety of public and private actors:
ffpublic and private donors
ffpharmaceutical companies
ffscientific research organizations
ffglobal policymakers and multilateral

organizations
ffnongovernmental organizations
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